BIOMAT Database Logo BIOMAT Database Logo

QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2006

Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
INIFTA, División Química Teórica, Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Diag. 113 y 64, Suc. 4 C. C. 16, (1900) La Plata, Argentina. pabloducho@yahoo.com.ar

By means of QSAR algorithms we model the potency pIC(90) [mM] of 154 non-nucleoside reverse transcriptase inhibitors (NNRTI) of the wild-type HIV-1 virus, considered as the second generation analogues of Efavirenz. In addition, 56 inhibitors of the K-103N viral mutant form are also investigated. A pool of 1494 theoretical molecular descriptors provided mainly by the Dragon 5 software is explored by several methods of variable selection: forward stepwise regression, the replacement method, and the genetic algorithm approach. The optimal models found include up to seven parameters: R = 0.7991, R(l-20%-o) = 0.7233 for the case of wild-type, and R = 0.9261, R(l-5%-o) = 0.8802 for the K-103N mutation.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D048588 Benzoxazines OXAZINES with a fused BENZENE ring. Benzoxazine,Benzoxazinoid,Benzoxazinone,Benzoxazinones,Benzoxazinoids
D052999 Quinazolinones Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen. Quinazolinedione,Quinazolinone,Quinazolinediones
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
The QSAR analysis of tricyclic non-nucleoside inhibitors of HIV-1 reverse transcriptase.
January 2003, Acta poloniae pharmaceutica,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
April 2012, Journal of molecular modeling,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT).
January 2002, Acta poloniae pharmaceutica,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
June 2003, AIDS (London, England),
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
March 2009, Bioorganic & medicinal chemistry,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
January 2016, Biological & pharmaceutical bulletin,
Pablo R Duchowicz, and Michael Fernández, and Julio Caballero, and Eduardo A Castro, and Francisco M Fernández
3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
August 2008, Journal of chemical information and modeling,
Copied contents to your clipboard!